検索結果

General Announcement: May 9, 2024 Senju Pharmaceutical Co., Ltd. Senju announces initiation of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion S...

Mytear EYETECT | OTC Products, etc. | Products | SENJU Pharmaceutical

ingredient, pranoprofen [swich OTC Drug], and is effective for teary eye, foreign body sensation (gritty or stinging sensation), itchy eyes, or redness of the conjunctiva due to inflammation of the ey...

ch 7, 2025 General Announcement Senju Pharmaceutical Co., Ltd. Announcement of Licensing Agreement with Brill International Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. S...

Compliance System | Our Initiatives for Society/Environment | About Senju | SENJU Pharmaceutical

yees and other members of Senju Pharmaceutical Co., Ltd. (“SENJU”) will act in compliance not only with the law but will operate under a high standard of ethical values so as to conduct business manag...

to Senju as an eye drop treatment for Dry Eye Disease (DED). We are pleased to announce today that it has been applied for manufacturing and marketing approval in Japan. DED, the target disease of SJ...